ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 61 of 97 for:    calcium cation

Impact of Intraoperative Fluid Management on Electrolyte and Acid-base Variables

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03054922
Recruitment Status : Enrolling by invitation
First Posted : February 16, 2017
Last Update Posted : February 27, 2018
Sponsor:
Information provided by (Responsible Party):
David P. Martin, Nationwide Children's Hospital

Brief Summary:
During major surgical procedures, intravascular volume is maintained with the administration of isotonic fluids such as Lactated Ringers (LR), Normal Saline (NS) or Normosol-R. All three of these fluids are in common clinical use for this purpose. As large volumes of NS may result in a dilutional acidosis and an increasing base deficit, it may cloud clinical decision making when resuscitative efforts are guided by acid-base status on routine arterial blood gas analysis. This is a prospective, randomized study to evaluate changes in acid-base and electrolyte (sodium, potassium, calcium) status with the use of various isotonic fluids for intraoperative resuscitation.

Condition or disease Intervention/treatment Phase
Anesthesia Drug: Normal Saline Drug: Lactated Ringer Drug: Normosol-R Inj Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Impact of Intraoperative Fluid Management on Electrolyte and Acid-base Variables
Actual Study Start Date : February 23, 2017
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Potassium

Arm Intervention/treatment
Active Comparator: Normal Saline
0.9% Sodium Chloride
Drug: Normal Saline
IV infusion of 0.9% NaCl throughout surgery.
Other Name: 0.9% NaCl

Active Comparator: Lactated Ringers

Each 100 mL of Lactated Ringer's Injection USP contains:

Sodium Chloride USP 0.6 g; Sodium Lactate USP 0.31 g; Potassium Chloride USP 0.03 g; Calcium Chloride Dihydrate USP 0.02 g; Water for Injection USP qs

Drug: Lactated Ringer
IV infusion of lactated ringer throughout surgery.

Active Comparator: Normosol-R
Each 100 mL of Normosol-R contains sodium chloride, 526 mg; sodium acetate, 222 mg; sodium gluconate, 502 mg; potassium chloride, 37 mg; magnesium chloride hexahydrate, 30 mg.
Drug: Normosol-R Inj
IV infusion of Normosol throughout surgery.




Primary Outcome Measures :
  1. Base deficit [ Time Frame: End of surgery (typically 4-6 hrs after baseline or start of surgery) ]
    Obtained from blood gas to measure metabolic acidosis


Secondary Outcome Measures :
  1. Sodium [ Time Frame: End of surgery (typically 4-6 hrs after baseline or start of surgery) ]
    Level of sodium electrolyte in blood

  2. Potassium [ Time Frame: End of surgery (typically 4-6 hrs after baseline or start of surgery) ]
    Level of potassium electrolyte in blood

  3. Ionized calcium [ Time Frame: End of surgery (typically 4-6 hrs after baseline or start of surgery) ]
    Level of calcium electrolyte in blood

  4. Fluid requirement [ Time Frame: End of surgery (typically 4-6 hrs after baseline or start of surgery) ]
    Amount of fluid required for resuscitation during surgery

  5. Urine output [ Time Frame: End of surgery (typically 4-6 hrs after baseline or start of surgery) ]
    Amount of urine produced during surgery



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   10 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Major surgical procedure requiring arterial access

Exclusion Criteria:

  • Comorbid disease process that contraindicates the use of any 1 of the 3 crystalloid solutions.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03054922


Locations
United States, Ohio
Nationwide Children's Hospital
Columbus, Ohio, United States, 43205
Sponsors and Collaborators
Nationwide Children's Hospital

Responsible Party: David P. Martin, Director, Acute Pain Services, Nationwide Children's Hospital
ClinicalTrials.gov Identifier: NCT03054922     History of Changes
Other Study ID Numbers: IRB16-01093
First Posted: February 16, 2017    Key Record Dates
Last Update Posted: February 27, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Plasma-lyte 148
Ophthalmic Solutions
Pharmaceutical Solutions